Arrow Pharmaceuticals is gearing up to unveil its Initial Public Offering (IPO) to the broader audience, signifying a pivotal moment in its growth and investment endeavors.
The firm intends to release 1.5 million units of common shares at a nominal value of Rs 100 per share. To streamline the IPO procedure, Arrow Pharmaceuticals has enlisted Global IME Capital as the designated issue manager.
A contract confirming this arrangement was signed on April 10 at the offices of Global IME Capital. The agreement was ratified by Udhab Prasad Mainali, Chairman of Arrow Pharmaceuticals, and Mandip Luitel, CEO of Global IME Capital.
Arrow Pharmaceuticals presently operates with a sanctioned capital of Rs 1 billion and an issued capital of Rs 750 million. The company’s headquarters is situated in Ward No. 3, Basundhara, Kathmandu Municipality, while its production facility is located in Sudal, Bhaktapur.
